INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Efficacy and Safety of Inhaled Dry Powder Mannitol in Treating Cystic Fibrosis: A Meta-Analysis and Systematic Review of Randomized Trials

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/21168

Files in this item

File Description Format
PDF Efficacy and Sa ... ed Dry Powder Mannitol.pdf (2MB) (no description provided) PDF
Title: Efficacy and Safety of Inhaled Dry Powder Mannitol in Treating Cystic Fibrosis: A Meta-Analysis and Systematic Review of Randomized Trials
Author(s): Jaeger, A; Moole, V; Dharmapuri, S; Boddireddy, R; Ernst, J; Moole, H; Chittivelu, S; Taneja, D
Subject(s): Inhaled mannitol Cystic fibrosis FEV1 Outcomes Metaanalysis Systematic review
Abstract: Background: Inhaled dry powder mannitol is an osmotic agent with a potential to improve lung functions in Cystic Fibrosis (CF) patients and possibly act as a disease modifying agent. Aim: Primary outcomes are to evaluate the improvement of lung functions. Methods Study selection criteria: Randomized trials that evaluated the improvement of lung functions in CF patients with the use of inhaled dry powder mannitol. Data collection & extraction: Articles were searched in Medline, Pubmed, and Ovid journals. Statistical method: Pooled proportions were calculated using fixed and random effects model. Results: Initial search identified 387 reference articles, of which 31 articles were selected and reviewed. Data was extracted from 6 studies (N = 771) which met the inclusion criteria. After the treatment duration (median12 weeks), FEV1% increased by 7.23 (95% CI = 6.88 to 7.58) and 2.77 (95% CI = 2.57 to 2.97) in the pooled patients of treatment and control groups respectively. FEV1 (in ml) improved by 114.12 (95% CI = 108.96 to 119.29) and 6.80 (95% CI = 6.13 to 7.48) in treatment and control groups respectively. Odds ratio for pharyngeal pain, cough, hemoptysis and headache in treatment group compared to control group were 1.52 (95% CI = 0.91 to 2.52), 1.27 (95% CI = 0.85 to 1.90), 1.82 (95% CI = 0.97 to 3.39) and 0.80 (95% CI = 0.54 to 1.19) respectively. Conclusion: Inhaled mannitol may be used as a chronic disease modifying treatment in patients with pulmonary CF and possibly improve the overall outcomes.
Issue Date: 2016-05-26
Publisher: Austin Publishing Group
Citation Info: Jaeger, A., V. Moole, S. Dharmapuri, R. Boddireddy, D. Taneja, and J. Ernst. "Efficacy and Safety of Inhaled Dry Powder Mannitol in Treating Cystic Fibrosis: A Meta-Analysis and Systematic Review of Randomized Trials." Austin Crit Care J 3, no. 1 (2016): 1015.
Type: Article
Description: This is a copy of an article published in the Austin Critical Care Journal. © Moole et al. www.austinpublishinggroup.com
URI: http://hdl.handle.net/10027/21168
ISSN: 2379-8017
Date Available in INDIGO: 2016-09-14
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 193
United Kingdom 50
Russian Federation 46
China 42
Germany 13

Browse

My Account

Information

Access Key